Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYT004-MelQbG10 Vaccine in Stage II Melanoma
NCT00306566Phase 2Completed
- Sponsor
- Cytos Biotechnology AG
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CYT004-MelQbG10 in Malignant Melanoma (MM), sponsored by Cytos Biotechnology AG. Primary endpoint: Safety and Tolerability. Status: completed.
02
Drugs
CYT004-MelQbG10
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT00306566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00306566.